The purpose of this trial is to determine the efficacy and safety of Moxifloxacin in comparison to Sulbactam/Ampicillin in the treatment of pulmonary abscesses and aspiration pneumonia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
139
Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
Unnamed facility
Mannheim, Baden-Wurttemberg, Germany
Unnamed facility
Nuremberg, Bavaria, Germany
Unnamed facility
Regensburg, Bavaria, Germany
Adverse events occuring after first application of study medication up to the test of cure visit for non-serious adverse events
Time frame: Up to 30 days after end of treatment with study medication for serious adverse events
Clinical Response
Time frame: Regulary doing i.v. treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Treuenbrietzen, Brandenburg, Germany
Unnamed facility
Frankfurt am Main, Hesse, Germany
Unnamed facility
Hildesheim, Lower Saxony, Germany
Unnamed facility
Rotenburg (Wümme), Lower Saxony, Germany
Unnamed facility
Lüdenscheid, North Rhine-Westphalia, Germany
Unnamed facility
Oberhausen, North Rhine-Westphalia, Germany
Unnamed facility
Paderborn, North Rhine-Westphalia, Germany
...and 5 more locations